Mutations of the tricarboxylic acid cycle enzyme fumarate hydratase cause hereditary leiomyomatosis and renal cell cancer 1 . Fumarate hydratase-deficient renal cancers are highly aggressive and metastasize even when small, leading to a very poor clinical outcome 2 . Fumarate, a small molecule metabolite that accumulates in fumarate hydratase-deficient cells, plays a key role in cell transformation, making it a bona fide oncometabolite 3 . Fumarate has been shown to inhibit α-ketoglutarate-dependent dioxygenases that are involved in DNA and histone demethylation 4,5 . However, the link between fumarate accumulation, epigenetic changes, and tumorigenesis is unclear. Here we show that loss of fumarate hydratase and the subsequent accumulation of fumarate in mouse and human cells elicits an epithelial-to-mesenchymal-transition (EMT), a phenotypic switch associated with cancer initiation, invasion, and metastasis 6 . We demonstrate that fumarate inhibits Tet-mediated demethylation of a regulatory region of the antimetastatic miRNA cluster 6 mir-200ba429, leading to the expression of EMT-related transcription factors and enhanced migratory properties. These epigenetic and phenotypic changes are recapitulated by the incubation of fumarate hydratase-proficient cells with cell-permeable fumarate. Loss of fumarate hydratase is associated with suppression of miR-200 and the EMT signature in renal cancer and is associated with poor clinical outcome. These results imply that loss of fumarate hydratase and fumarate accumulation contribute to the aggressive features of fumarate hydratase-deficient tumours.
UOK262 cells exhibited strong vimentin expression (Extended Data Fig. 3b-d) , and increased migration (Extended Data Fig. 3e ) compared to UOK262pFH cells. However, localization of E-cadherin at the plasma membrane was not observed in UOK262pFH cells (Extended Data Fig. 3d ).
EMT is orchestrated by several transcription factors, including TWIST1, TWIST2, SNAI1, SNAI2, ZEB1 and ZEB2 (ref 9) . Twist1, which is activated by the hypoxia-inducible factor HIF1 (ref. 10 ), a key player in FH-deficient tumours 11 , was elevated in Fh1-deficient cells (Fig. 1h ). The silencing of HIF1β , the constitutively expressed subunit of HIFs that is required for their transcriptional activity 12 , failed to reduce the expression of EMT markers (Extended Data Fig. 4a, b ), suggesting that EMT in Fh1-deficient cells is probably independent of HIF. Snai2, Zeb1 and Zeb2 were also induced in Fh1-deficient cells, and their expression was reversed by Fh1 re-expression in these cells ( Fig. 1h, i) . ZEB2 expression was also decreased upon restoration of FH in UOK262 cells (Extended Data Fig. 3f ). Expression of Snai2, Zeb1 and Zeb2 is suppressed by the antimetastatic miRNAs miR-200ba429 and miR-200c141 (ref. 6) . miRNA profiling revealed that miR-200 family members were among the most downregulated miRNAs in Fh1deficient cells ( Fig. 2a ). Suppression of miR-200 was also observed in UOK262 cells compared to non-transformed HK2 cells, and was partially restored by FH re-expression (Extended Data Fig. 3g , h). Quantitative PCR (qPCR) confirmed the miRNA profiling results and showed that the reconstitution of Fh1 expression in Fh1-deficient cells restored the expression of miR-200a and miR-200b and, in part, that of miR-200c and miR-141 ( Fig. 2b ). We hypothesized that the partial restoration of miR-200c141 expression could be ascribed to the residual fumarate in Fh1 −/− +pFh1 cells (Extended Data Figs 1c, 5b) , which could also explain the partial recovery of the EMT gene signature (Extended Data Fig. 2a-c) . Blunting fumarate levels by re-expressing high levels of Fh1 in Fh1 −/− cells rescued their phenotype (Extended Data Fig. 5b -g) and led to full reactivation of the entire miR-200 family (Extended Data Fig. 5h ), indicating that members of this family have a different susceptibility to fumarate. The incomplete rescue of fumarate levels in UOK262pFH cells 7 could also explain the partial restoration of miRNAs and some EMT markers in these cells.
As miR-200ba429 expression was fully restored in Fh1 −/− +pFh1 cells and its expression was sufficient to suppress vimentin and rescue E-cadherin expression in Fh1-deficient cells (Fig. 2c) , we investigated the role of this miRNA cluster in Fh1-dependent EMT. Repression of miR-200 expression is associated with its epigenetic silencing via CpG island hypermethylation 13 , which can also be caused by downregulation of the Tet family of methylcytosine dioxygenases 14, 15 . We hypothesized that fumarate could cause suppression of miR-200ba429 by inhibiting Tet-mediated demethylation. The combined silencing of Tet2 and Tet3, which encode the most abundant Tet isoforms in Fh1 fl/fl cells (Extended Data Fig. 6a ), but not the inhibition of α -ketoglutarate (aKG)-dependent histone demethylases by GSK-J4 (ref. 16 ), decreased expression of miRNAs and E-cadherin (Extended Data Fig. 6b-e ), highlighting the role of Tets in regulating EMT 14, 15 . A Genome Browser 17 view of an ENCODE data set generated in mouse kidney cells revealed a conserved CpG island at the 5′ end of mir-200ba429, CpG43, that is were used as endogenous controls for mRNA and miRNA, respectively. NTC, non-targeting control. d, Methylation-specific PCR of CpG43. U, unmethylated; M, methylated CpG island. The mir-200ba429 cluster (blue) and CpG43 (green) are represented in the schematic. qPCR results were obtained from at least three independent cultures and presented as RQ with maximum values. P values calculated using unpaired t-test. * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001, * * * * P ≤ 0.0001. For gel source images, see Supplementary Fig. 1 . For source data, see Supplementary Table 2 . enriched in binding sites for Tets and for lysine-methylated histone H3 (Extended Data Fig. 7a ). Chromatin immunoprecipitation (ChIP) experiments showed that a region adjacent to CpG43 was enriched for the repressive marks H3K9me2 and H3K27me3 and depleted of the permissive marks H3K4me3 and H3K27Ac in Fh1-deficient cells (Extended Data Fig. 7b ) in the absence of changes in total H3K4 and H3K27 methylation among Fh1-proficient and Fh1-deficient mouse cells (Extended Data Fig. 7c ). Chromosome conformation capture (3C) analysis 18 identified a physical association between this regulatory region and the transcription starting site of mir-200ba429, which sits in the intronic region of the gene Ttll10 (Extended Data Fig. 7d ). This region was hypermethylated in Fh1-deficient cells and the re-expression of Fh1 restored its methylation levels ( Fig. 2d and Extended Data Fig. 7e ). Binding of Tets to CpG43 was comparable among the cell lines tested (Extended Data Fig. 7f ), suggesting that the changes in methylation of this region are, at least in part, caused by inhibition of the activity of Tet enzymes rather than by their differential binding to chromatin. Consistently, 5-hydroxymethylcytosine (5hmC), the product of oxidation of 5-methylcytosine by Tets 15 , was significantly decreased in Fh1-deficient cells (Extended Data Fig. 7g ).
Incubating cells with dimethyl aKG (DM-aKG), a cell-permeable derivative of aKG that is known to reactivate aKG-dependent dioxygenases 19 , restored the expression of miR-200a in Fh1-deficient cells (Extended Data Fig. 6f ). Conversely, treating Fh1 fl/fl and human FH-proficient epithelial kidney (HK2) cells with monomethyl fumarate (MMF), a cell-permeable derivative of fumarate, triggered profound phenotypical (Extended Data Fig. 8a ) and (epi)genetic ( Fig. 3a -g) changes that resembled those of FH-deficient cells. However, unlike Fh1 −/− cells ( Fig. 1h ), MMF-treated Fh1 fl/fl cells did not show induction of Snai2 (Fig. 3c ). Furthermore, MMF-treated HK2 cells did not show changes in vimentin, which is expressed in HK2 cells 20 despite their epithelial origin. MMF did not cause mitochondrial dysfunction but led to a typical fumarate-dependent metabolic signature, characterized in both cell types by accumulation of fumarate and fumarate-derived succinic-GSH (succGSH) and 2-succinic-cysteine (2SC) 21, 22 (Extended Data Fig. 8b , c and Supplementary Table 3 ). To rule out the possibility that by-products of fumarate accumulation, rather than fumarate itself, elicit EMT, we analysed the effects of accumulation of succinate, another metabolite that can inhibit Tets 3-5 , but cannot promote succination. Because we could not increase succinate levels with cell-permeable dimethyl succinate (Extended Data Fig. 9a ) we used succinate dehydrogenase b (Sdhb)-deficient cell lines 23 , which accumulate succinate but not fumarate by-products, including succGSH (Extended Data Fig. 9b , c). These cells exhibited striking mesenchymal features (Extended Data Fig. 9d , e), and epigenetic suppression of the miR-200ba429 family (Extended Data Fig. 9f , g), in line with the hypermethylation phenotype and EMT signature observed in SDH-deficient cells 24 .
We next investigated the link between FH loss, fumarate accumulation and EMT in renal cancer samples. Vimentin was highly expressed and E-cadherin was suppressed in a previously published data set 25 of hereditary leiomyomatosis and renal cell cancer (HLRCC) tumour samples, when compared to normal tissue (Extended Data Fig. 10a ). Two HLRCC tumours that we profiled exhibited increased fumarate ( Fig. 4a ), decreased 5hmC levels ( Fig. 4b ) but comparable TET enzyme levels (Extended Data Fig. 10b ), miR-200 suppression (Fig. 4c) , marked Supplementary Table 2 . vimentin staining and loss of E-cadherin (Extended Data Fig. 10b ) when compared to matched normal tissue. We also took advantage of data from a collection of papillary renal-cell carcinoma (KIRP) samples, a tumour type associated with loss of FH 26 . These tumours exhibited a partial EMT signature (Extended Data Fig. 10c ) and downregulation of miR-200 (Extended Data Fig. 10d ). FH levels were positively correlated with patient survival (Extended Data Fig. 10e ), consistent with the poor prognosis associated with EMT 6 . The five FH-mutant tumours in this cohort exhibited overexpression of vimentin and suppression of E-cadherin (Extended Data Fig. 10f ), hypermethylation and suppression of miR-200A and miR-200B ( Fig. 4d, e ) in the absence of TET mutations (Extended Data Fig. 10g ). These tumours were associated with the worst prognosis among papillary cancers (Extended Data Fig. 10h ). FH mRNA was also significantly decreased in a panel of clear cell renal carcinomas (KIRC) 27 (Extended Data Fig. 10i ) and its levels correlated negatively with vimentin (Pearson correlation coefficient of − 0.5, P < 10 −5 ; Fig. 4f ) and positively with E-cadherin (Pearson correlation coefficient of 0.22, P < 10 −5 ; Fig. 4g ), and were positively correlated with patient survival (Extended Data Fig. 10k ), confirming the role of FH in tumour malignancy and patient outcome.
Our results report a link between the loss of FH and epigenetic suppression of miR-200 mediated by fumarate (see Extended Data Fig. 1f for a schematic). Although other mechanisms could contribute to fumarate-driven EMT, our findings offer an explanation for the suppression of miR-200 in papillary and clear-cell renal carcinomas and the expression of EMT-related transcription factors, including ZEB2, in KIRC 28 . Our data imply that dysregulation of FH activity and fumarate accumulation are involved in EMT induction and may feature in other tumour types where FH loss has been reported, including neuroblastoma 29 and colorectal and lung cancer 30 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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METHODS
Cell culture. Fh1-proficient (Fh1 fl/fl ) cells and the two Fh1-deficient clones (Fh1 −/−CL1 and Fh1 −/−CL19 ) were obtained as previously described 7 . Fh1 −/− +pFh1 cells were single clones generated from Fh1 −/−CL19 after stable expression of a plasmid carrying mouse wild-type Fh1 (Origene, MC200586). Mouse cells were cultured using DMEM (Gibco-41966-029) supplemented with 10% heat-inactivated serum (Gibco-10270-106) and 50 μ g ml −1 uridine. Genotyping of cells was assessed as previously described 7 . Human FH-deficient (UOK262) and FH-restored (UOK262pFH) cells were obtained as previously described 7 and cultured in DMEM (Gibco-41966-029) supplemented with 10% heat-inactivated serum (Gibco-10270-106). HK2 cells were a gift from the laboratory of E.R.M. These cells were authenticated by short tandem repeat and cultured in DMEM (Gibco-41966-029) supplemented with heat-inactivated 10% serum. All cell lines were tested for mycoplasma contamination using MycoProbe Mycoplasma Detection Kit (R&D Systems CUL001B) and were confirmed mycoplasma-free. Generation of Fh1 −/− +pFh1-GFP cells. The Fh1-GFP vector was generated by amplifying wild-type Fh1 sequence using cDNA generated from Fh1 fl/fl cells by PCR. Restriction overhangs (KpnI, EcoRI) were included in the primer sequence to allow restriction enzyme cloning of Fh1 into the backbone vector pEF1α -V5/His (Life Technology). We then used a two-step PCR 'restriction-free' method to swap the V5-His sequence within pEF1α with the AcGFP sequence to yield a fusion protein, Fh1-GFP. 10 5 Fh1 −/− CL1 cells were plated onto 6-well plates and the day after transfected with the Fh1-GFP vector using Lipofectamine 2000 following the manufacturer's instructions. After 2 weeks, cells were sorted for GFP expression and the medium-expressing population was maintained in culture and amplified. A pEF1α -GFP empty vector was used as control. Primers for cloning are listed in Supplementary Table 1 . Short hairpin RNA (shRNA) interference experiments. Lentiviral particles for shRNA delivery were obtained as previously described 7 from the filtered growth medium of 2 × 10 6 HEK293T cells transfected with 3 μ g psPAX, 1 μ g pVSVG and 4 μ g of the plasmid of interest using Lipofectamine 2000/3000 (Life Technology). 10 5 cells of the indicated genotype were then plated onto 6-well plates and infected with the viral supernatant in the presence of 4 μ g ml −1 polybrene. After two days, the medium was replaced with selection medium containing 1 μ g ml −1 puromycin. pGIPZ vectors for shRNA against mouse Hif1b (also known as Arnt; RMM4532-EG11863), Tet2 (RMM4532-EG214133) and Tet3 (RMM4532-EG194388) were purchased from GE Healthcare UK. pLenti 4.1 Ex for expression of miRNAs was purchased from Addgene (Plasmid #35533 and #35534). pLenti 4.1 Ex scrambled vector was generated by cloning a scrambled DNA sequence taken from a commercially available vector (pCAG-RFP-miR-Scrint Addgene no. 198252) into the empty backbone. RNA extraction and real-time PCR. Cells were plated the day before the experiments onto 6-well plates (3 × 10 5 ) or 12-well plates (10 5 ). Total RNA was isolated using RNeasy Kit (Qiagen). miRCURY RNA Isolation Kit (Exiqon) was used for miRNA extraction. RNA isolation was carried out following the manufacturer's protocols. RNA was quantified using the fluorimeter Qubit 2.0 (Life Technologies) following the manufacturer's instructions or Nanodrop (Thermo). Reverse transcription of RNA was performed using Quantitect-Reverse transcription kit (Qiagen) or miScript PCR kit (Qiagen) using 300-500 ng total RNA. Real-time qPCR was performed using Quantitect Syber Green master mix (Qiagen) or Taqman universal mix (Life Technology) on a Step One Plus real-time PCR system (Life Technology). Experiments were analysed using the software Expression Suite (Life Technology) and StepOne software 2.3 and relative quantification (RQ) with max and min values (RQ max and RQ min) were calculated using the s.d. algorithm. Statistical analysis was performed using Expression Suite software on at least three independent cultures. Housekeeping genes used for internal normalization were Actb for mRNA and Snord95, Snord61 and RNU6-6P for miRNAs. The primers were designed using ProbeFinder (Roche) or purchased from Qiagen and are listed in Supplementary Table 1 . miRNA methylation analyses. 5 × 10 5 cells were plated onto 6-cm dishes. Their genomic DNA was extracted using DNeasy kit (Qiagen), and purified using DNA Cleaning and Concentrator kit (Zymo Research) following the manufacturer's instructions. Genomic DNA (20 ng per well), quantified using Qubit, was digested using OneStep qMethyl kit (Zymo Research) following the manufacturer's protocol. Primers used are listed in Supplementary Table 1 .
For the methyl-specific PCR (MSP) assay, 500 ng of purified DNA was bisulfate converted using the EZ-DNA Methylation-direct kit (Zymo Research) following the manufacturer's datasheet. 50 ng bisulfate-converted DNA, quantified using a Nanodrop spectrofluorimeter, were used for PCR reaction with AmpliTaq Gold (Life Technology) following the manufacturer's protocol. Thirty amplification cycles were used. Methylation-specific primers were designed using MethPrimer 31 (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) and are listed in Supplementary Table 1 .
Migration assay. Migration experiments were performed using xCELLigence instrument (ACEA Biosciences). In brief, 5 × 10 4 cells were plated onto cell invasion/ migration (CIM) plates in medium supplemented with 1% FBS. Complete medium with 20% FBS was used as a chemoattractant. Migration was registered in real time for at least 24 h and the cell index was calculated using the appropriate function of the xCELLigence software. Motility assay. The day before the experiment, 5 × 10 4 mouse cells of the indicated genotype were plated onto 6-cm dishes. The next day, the medium was replaced with fresh medium containing Hoechst (Sigma-Aldrich) and cells were incubated for 15 min at 37 °C with 5% CO 2 before starting recording. Images were collected every minute for 3 h using a Zeiss Axiovert 200M microscope with a 10× objective. Analysis of cell movement was performed using cell tracker (http://www.celltracker. website) implemented in MATLAB (MATLAB R2013b, MathWorks) as previously described 32 . Three replicates were analysed for each cell type. All tracks were examined and those belonging to non-isolated cells deleted. The average speed for each cell was calculated as the sum length of the cell's trajectory divided by the total time over which the trajectory was measured. As the data were not normally distributed (Shapiro-Wilk test), a Mann-Whitney test was used to compare the average speeds of the cells. Oxygen consumption rate and extracellular acidification rate measurements. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using the real-time flux analyser XF-24e (Seahorse Bioscience) as previously described 7 . In brief, 4 × 10 4 cells were left untreated and then treated with 1 μ M oligomycin, 2 μ M carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), rotenone and antimycin A (both 1 μ M) (all Sigma-Aldrich). At the end of the run, cells were lysed using RIPA buffer (25 mM Tris/HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). The protein content of each well was measured using a BCA kit (Pierce) following the manufacturer's instruction. OCR and ECAR were normalized to total protein content as indicated. Immunofluorescence experiments. 5 × 10 4 cells were plated onto chamber slides (Laboratory Tech), cultured in standard conditions overnight and then fixed using 100% methanol for 2 min at -20 °C. After two washes in PBS, cells were permeabilized and incubated with blocking solution (BSA 2%, 0.1% Triton X-100, 0.1% Tween 20 in PBS) for 30 min at room temperature. Cells were then incubated with the primary antibody (overnight at 4 °C). For 5hmC staining, cells were grown on coverslips onto a 12-well plate. Cells were then fixed with 4% PFA in PBS for 15 min at room temperature, washed three times in PBS and then incubated for 15 min with 0.4% Triton X-100 in PBS. After three washes in PBS, cells were denatured using a solution of 2 M HCl for 15 min at room temperature and neutralized using 100 mM Tris pH 8 for 5 min After three washes in PBS, cells were incubated with blocking solution (5% FBS, 0.1% Triton X-100, 0.1% Tween 20 in PBS) for 1 h and then primary antibody was added at 4 °C overnight. After three washes in PBS, cells were incubated with secondary antibody for 2 h at room temperature and then slides or coverslips were mounted (Vectashield with DAPI) and images taken using a Leica confocal microscope TCS SP5 with 20× or 40× objectives. Laser intensity, magnification, and microscope settings per each channel were maintained equal throughout the different experimental conditions. Antibodies used are listed in Supplementary Table 1 . Protein lysates and western blotting. Cell lysates were prepared in RIPA buffer. Protein content was measured using a BCA kit (Pierce) following the manufacturer's instructions. 50-100 μ g protein was heated at 70 °C for 10 min in the presence of Bolt loading buffer 1× supplemented with 4% β -mercaptoethanol (Sigma). Samples were then loaded onto Bolt gel 4-12% Bis-Tris (Life Technology) and run using MOPS 1× or MES 1× buffer at 165 V constant for 40 min. Dry transfer of the gels was carried out using IBLOT2 system (Life Technology). Membranes were then incubated in blocking buffer (5% BSA or 5% milk in TBS 1× + 0.01% Tween 20) for 1 h at room temperature. Primary antibodies in blocking buffer were incubated overnight at 4 °C. Secondary antibodies (conjugated with 680 or 800 nm fluorophores from Li-Cor) were diluted 1:2,000 in blocking buffer and incubated for 1 h at room temperature. Images were acquired using Odyssey software (Li-Cor). Primary antibodies are listed in Supplementary Table 1 . Chronic treatment of mouse and human cells. Fh1 fl/fl cells were cultured either with 200 μ M monomethyl-fumarate (MMF, Sigma-Aldrich) for 2 weeks and then with 400 μ M MMF for the following 6 weeks, or with 4 mM monomethyl-succinate (MMS, Sigma-Aldrich) for 8 weeks. HK2 cells were cultured with MMF 400 μ M for 8 weeks. Fh1 −/− cells were treated with the indicated doses of dimethyl aKG (DM-aKG, Sigma-Aldrich) for 24 h. Fh1 fl/fl cells were treated with histone demethylase inhibitor GSKJ4 (Tocris) 1 μ M for 8 weeks. MMF, MMS and GSK-J4 were added twice a week after passaging the cells. ChIP-PCR. ChIP was performed as previously described 33 . Enrichment was determined by real-time PCR and the ChIP signal was normalized to input, IgG-only ChIP and negative control (genomic region devoid of histone markers). For Tet ChIP-PCR, the signal was normalized over input and IgG ChIP, as Tet-specific genomic negative controls are not as readily identifiable. Antibodies and primers for ChIP-PCR are indicated in Supplementary Table 1 . Chromatin conformation capture (3C) assay. 3C assay coupled with quantitative PCR (qPCR) was performed as previously described 18 . In brief, 10 7 cells were crosslinked with 1% formaldehyde for 10 min at room temperature and were quenched with glycine. Cells were then lysed by dounce homogenization in ice-cold lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% Igepal CA-630, all Sigma) supplemented with protease inhibitor (Roche). Cells were then washed in 1.2× NEB buffer 2 (New England Biolabs). Non-crosslinked proteins were removed with SDS (Sigma-Aldrich) and then quenched with Triton X-100. Chromatin was digested overnight with EcoRI restriction enzyme (New England Biolabs). Afterwards EcoRI was inactivated by heating at 65 °C for 20 min In-nuclear DNA ligation was performed at 16 °C for 4 h in the mixture containing 1× T4 DNA ligase buffer (New England Biolabs), 10 mg ml −1 BSA (New England Biolabs), and 1 U μ l −1 T4 DNA ligase (Invitrogen). The ligation mixture was then incubated with Proteinase K (Roche) at 65 °C overnight to reverse the crosslinking and was incubated with RNase A (Roche) at 37 °C for 1 h. DNA was purified with phenol (pH 8.0, Sigma) once and then with phenol:chloroform:isoamyl alcohol (25:24:1, pH 8.0, Sigma), followed by ethanol precipitation by adding 2.5 volume of ice-cold 100% ethanol and 1/10 volume of 3 M sodium acetate (pH 5.2, Lonza). The DNA pellet was washed with 70% ethanol twice and was eventually dissolved in 100 μ l distilled water. The concentration of 3C DNA was determined by Qubit dsDNA HS assays (Invitrogen). 100 ng DNA was taken to run qPCR in duplicate wells for each 3C sample, using Taqman Universal PCR Master Mix (Applied Biosystems) and specific Taqman primers and probes on ABI 7900 (Applied Biosystems) following the manufacturer's instruction. Data were analysed as recommended 18 and were normalized to the internal loading control of the Gapdh locus. Calculation of primer locations was based on the transcription start site (TSS) of the Ttll10 transcript (ENSMUST00000097731). Oligonucletide sequences are listed in Supplementary Table 1 . Metabolomic analyses. 3 × 10 5 cells were plated onto a 6-well plate and cultured in standard conditions for 24 h. Medium was replenished with fresh medium and, after 24 h, intracellular metabolites were extracted as previously described 21 . Liquid chromatography-mass spectrometry (LC-MS) analysis was performed on a QExactive Orbitrap mass spectrometer coupled to a Dionex UltiMate 3000 Rapid Separation LC system (Thermo). The LC system was fitted with either a SeQuant Zic-HILIC column (column A, 150 mm × 4.6 mm, 5 μ m), or a SeQuant Zic-pHILIC (column B, 150 mm × 2.1 mm, 5 μ m) with the corresponding guard columns (20 mm × 2.1 mm, 5 μ m) both from Merck. With column A, the mobile phase was composed of 0.1% aqueous formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The flow rate was set at 300 μ l min −1 and the gradient was as follows: 0-5 min 80% B, 5-15 min 15 min 30% B, 15-20 min 10% B, 20-21 min 80% B, hold at 80% B for 9 min For column B, the mobile phase was composed of 20 mM ammonium carbonate and 0.1% ammonium hydroxide in water (solvent C), and acetonitrile (solvent D). The flow rate was set at 180 μ l min −1 with the following gradient: 0 min 70% D, 1 min 70% D, 16 min 38% D, 16.5 min 70% D, hold at 70% D for 8.5 min The mass spectrometer was operated in full MS and polarity switching mode. Samples were randomized, in order to avoid machine drift, and were blinded to the operator. The acquired spectra were analysed using XCalibur Qual Browser and XCalibur Quan Browser softwares (Thermo Scientific) by referencing to an internal library of compounds. Calibration curves were generated using synthetic standards of the indicated metabolites. Proteomics analysis. Proteomics experiments were performed using mass spectrometry as reported 34, 35 . In brief, cells were lysed in urea lysis buffer (8 M urea, 10 mM Na 3 VO 4 , 100 mM β -glycerol phosphate and 25 mM Na 2 H 2 P 2 O 7 and supplemented with phosphatase inhibitors (Sigma)) and proteins reduced and alkylated by sequential addition of 1 mM DTT and 5 mM iodoacetamide. Immobilized trypsin was then added to digest proteins into peptides. After overnight incubation with trypsin, peptides were desalted by solid phase extraction (SPE) using OASIS HLB columns (Waters) in a vacuum manifold following the manufacturer's guidelines with the exception that the elution buffer contained 1 M glycolic acid.
Dried peptide extracts were dissolved in 0.1% TFA and analysed by nanoflow LC-MS/MS in an LTQ-orbitrap as described 34, 35 . Gradient elution was from 2% to 35% buffer B in 90 min with buffer A being used to balance the mobile phase (buffer A was 0.1% formic acid in water and B was 0.1% formic acid in acetonitrile). MS/MS was acquired in multistage acquisition mode. MS raw files were converted into Mascot Generic Format using Mascot Distiller (version 1.2) and searched against the SwissProt database (version 2013.03) restricted to human entries using the Mascot search engine (version 2.38). Allowed mass windows were 10 ppm and 600 mmu for parent and fragment mass to charge values, respectively. Variable modifications included in searches were oxidation of methionine, pyro-glu (N-term) and phosphorylation of serine, threonine and tyrosine. Results were filtered to include those with a potential for false discovery rate less than 1% by comparing with searches against decoy databases. Quantification was performed by obtaining peak areas of extracted ion chromatographs (XICs) for the first three isotopes of each peptide ion using Pescal 36, 37 . To account for potential shifts in retention times, these were re-calculated for each peptide in each LC-MS/MS run individually using linear regression based on common ions across runs (a script written in python 2.7 was used for this retention time alignment step). The mass and retention time windows of XICs were 7 ppm and 1.5 min, respectively. Toray miRNA array. Initial sample quality control was performed using a Bioanalyzer 2200 system in conjunction with the Total RNA Nano chip (Agilent). 250 ng total RNA was labelled using the miRCURY LNA microRNA Hy5 Power labelling kit (Exiqon) according to the Toray array protocol. Samples were hybridized to the Human/Mouse/Rat miRNA 4-plex miRBase v17 array (Toray) and subsequently scanned using the 3D-Gene Scanner 3000 (Toray) according to the manufacturer's instructions. Data were normalized according to instructions provided by Toray. Briefly, the presence or absence of signals was determined using a cut off defined as the mean of the middle 90% of the blank control intensities (background average intensity) + 2σ. Positive control signals were removed and the background average intensity subtracted from the signal intensities to give the background subtracted signal intensities (y). Normalized signal intensities (NSI) were then calculated as follows: NSI = 25y/(y). Raw data are presented in Supplementary Table 4 . MS-based analysis of methylated DNA from HLRCC tumours. DNA from healthy and tumour tissue was extracted using DNeasyKit (Qiagen) following the manufacturer's instructions. 0.5-1 μ g DNA resuspended in 25 μ l water was first denatured at 100 °C for 30 s, cooled on ice, and 2 μ l ZnSO 4 (20 mM) was added. DNA was digested at 50 °C for 16 h using 1 μ l Nuclease P1 (200 U ml −1 , Sigma Aldrich) and dephosphorylated at 65 °C for 2 h by adding 1 μ l bacterial alkaline phosphatase (BAP) (150 U μ l −1 , Life Technology). The pH was then adjusted using 30 μ l 0.5 M Tris-HCl pH 7.9 for 1 h at 37 °C.
Analysis of global levels of C, 5hmC and 5mC was performed on a QExactive Orbitrap mass spectrometer coupled to a Dionex UltiMate 3000 Rapid Separation LC fitted with an Acquity UHPLC HSS T3 column (100 × 2.1 mm, 1.8). The mobile phase consisted of 0.1% aqueous formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B) at a flow rate of 300 μ l min −1 . Calibration curves were generated using synthetic standards for 2′ -deoxycytidine and 5-methyl-and 5-hydroxymethyl-2′ -deoxycytidine (Berry&Associates). The mass spectrometer was set in a positive ion mode and operated in parallel reaction monitoring. Ions of masses 228.10, 242.11, and 258.11 were fragmented and full scans were acquired for the base fragments 112.0505, 126.0661, and 146.0611 ± 5 ppm (corresponding to C, 5mC and 5hmC, respectively). The extracted ion chromatogram (EIC) of the corresponding base-fragment was extracted using the XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Scientific), and used for quantification. Quantification was performed by comparison with the standard curve obtained from the pure nucleoside standards running with the same batch of samples. The level of 5hmC present in the sample was expressed as a percentage of total cytosine content. Immunohistochemistry on HLRCC tumours. Specimens were formalin fixed and embedded in paraffin wax; 3-μ m serial sections mounted on Snowcoat X-tra slides (Surgipath, Richmond, Illinois) were dewaxed in xylene and rehydrated using graded ethanol washes. For antigen retrieval, sections were immersed in preheated DAKO target retrieval solution (DAKO) and treated for 90 s in a pressure cooker. Sections analysed contained both tumour and adjacent normal renal parenchyma acting as an internal control; in addition, substitution of the primary antibody with antibody diluent was used as a negative control. Antigen-antibody complexes were detected using the Envision system (DAKO) according to the manufacturer's instructions. Sections were counterstained with haematoxylin for 30 s, dehydrated in graded ethanol washes, and mounted in DPX (Lamb). Antibodies used were: E-cadherin (HECD1, CRUK) and vimentin (clone V9, Dako). TET1 (SAB 2501479) and TET2 (HPA 019032) antibodies were purchased from Sigma Aldrich. miRNA expression on HLRCC tumours. Total RNA was extracted from tumour and healthy tissue using miRCURY kit (Exiqon, Denmark) following the manufacture's protocols. RNA reverse-transcription and real-time qPCR were carried out as described above. Data were normalized to healthy tissue using SNORD61 and RNU6-6P as endogenous controls. Fig. 1g . Results were generated from three independent cultures. g, mRNA expression of EMT-related transcription factors. Actb was used as endogenous control. EV, empty vector. h, Expression levels of the indicated miRNAs measured by qPCR and normalized to Snord95 and Snord61 as endogenous controls. All qPCR results were obtained from three independent cultures and presented as RQ with maximum values. * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001, * * * * P ≤ 0.0001. Western blot source images are presented in Supplementary Fig. 1 . Source data are presented in Supplementary Table 2. 
